Complete response of a highly advanced gastric carcinoma to preoperative chemoradiotherapy with S-1 and low-dose cisplatin

Gastric Cancer

Volumn 6, Issue 3, 2003, Pages 185-190

  Yoshimizu, Nobunari ^a   Saikawa, Yoshiro ^a   Kubota, Tetsuro ^a   Akiba, Yasutada ^a   Yoshida, Masashi ^a   Otani, Yoshihide ^a   Kumai, Koichiro ^a   Hibi, Toshihumi ^a   Kitajima, Masaki ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Cisplatin; Complete response; Gastric cancer; Radiation; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CASE REPORT; DISEASE COURSE; GASTRECTOMY; GASTROINTESTINAL DISEASE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKOPENIA; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; MULTIMODALITY CANCER THERAPY; POSTOPERATIVE COMPLICATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RADIATION RESPONSE; SPLENECTOMY; STOMACH CARCINOMA; THROMBOCYTOPENIA;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; GASTROSCOPY; HUMANS; MALE; NEOADJUVANT THERAPY; OXONIC ACID; PYRIDINES; RADIOTHERAPY, ADJUVANT; STOMACH NEOPLASMS; TEGAFUR; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 0141892587     PISSN: 14363291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10120-003-0239-2     Document Type: Article

References (20)

1. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: fifth edition. American joint committee on cancer staging, proximal disease, and the "different disease" hypothesis. Cancer 2000;88:921-32.
2. Landry J, Tepper JE, Wood WC, Moulton EO, Koerner F, Sullinger J. Patterns of failure following curative resection of gastric cancer. Int J Radiat Oncol Biol Phys 1990;191:1357-62.
3. Ochiai T, Hayashi H, Suzuki T, Nakajima K, Shimada H, Hishikawa E, et al. Evaluation of a new staging system by the Japanese Research Society for Gastric Cancer. Surg Today 1998;28:1015-21.
4. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stermmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-30.
5. Waters JS, Norman A, Cunningham D, Scarffe JH, Webb A, Herper P, et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 1999;80:269-72.
6. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Trace Cancer Cooperative Group. J Clin Oncol 2000;18:2648-57.
7. Ravaud A, Borner M, Schellens JH, Geoffrois L, Schoffski BP, Kroon K, et al. EORTC-ECSG. UFT and leucovorin in first-line chemotherapy for patients with metastatic gastric cancer. An Early Clinical Studies Group (ECSG)/European Organization for Research and Treatment of Cancer (EORTC) phase II trial. Eur J Cancer 2001;37:1642-7.
8. Garcia AA, Leichman CG, Lenz HJ, Baranda J, Lujan R, Casagrande Y, Leichman L. Phase II trial of outpatient schedule of paclitaxel in patients with previously untreated metastatic, measurable adenocarcinoma of the stomach. Jpn J Clin Oncol 2001;31:275-8.
9. Harris BE, Song R, Soong ST, Diasio RB. Relationship between dihydropyrimidine dehydrogenase activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990;50:197-201.
10. Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996;7:548-57.
11. Shirasaka K, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993;53:4004-9.
12. Sugimachi K, Maehara Y, Horikoshi N, Shimada Y, Sakata Y, Mitachi Y, Taguchi T. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group. Oncology 1999;57:202-10.
13. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur-0.4M gimestat-1M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998;34:1715-20.
14. Chung YS, Yamashita Y, Inoue T, Matsuoka T, Nakata B, Onoda N, et al. Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma. Cancer 1997;80:1-7.
15. Shirasaka T, Yamamitsu S, Tsuji A, Taguchi T. Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan. Invest New Drugs 2000;18:315-29.
16. Iwahashi M, Nakamori M, Tani M, Yamaue H, Sakaguchi S, Nakamura M, et al. Complete response of highly advanced gastric cancer with peritoneal dissemination after new combined chemotherapy of S-1 and low dose cisplatin: report of a case. Oncology 2001;61:16-22.
17. Japanese Research Society for Gastric Cancer. Japanese classification of gastric carcinoma. 16th Ed. Tokyo: Kanehara; 2001.
18. Official reference of CTC version 2.0: Cancer Therapy Evaluation Program. Common Toxicity Criteria, Version 2.0. DCTD, NCI, NIH, DHHS 1998.
19. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
20. Saikawa Y, Akasaka Y, Kanai T, Otani Y, Kumai K, Kubota T, Kitajima M. Preoperative combination chemotherapy with S-1 and low dose cisplatin against highly advanced gastric carcinoma. Oncol Rep 2003;10:381-6.